1-3 of 3
Tamara Everington
Close
Sort by
Journal Articles

101HEMB01 Is a Phase 1/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Moderate/Severe Hemophilia B That Demonstrated Meaningful but Transient Expression of Human Factor IX (hFIX)

Steven Pipe, MD, Kimo Stine, MD, Anita Rajasekhar, MD, Tamara Everington, MD, Allen Poma, MD, Eric Crombez, MD, Charles RM Hay, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3331.
https://doi.org/10.1182/blood.V130.Suppl_1.3331.3331
Published: 2017
Journal Articles

Midostaurin a Multi-Targeted Oral Kinase Inhibitor in Systemic Mastocytosis: Report of An Open-Label Compassionate Use Program in the United Kingdom

Steven Knapper, DM MRCP FRCPath, Jonathan Cullis, Mark W. Drummond, PhD, FRCPath, MB, CHB, Roger Evely, Tamara Everington, Christine Hoyle, Lorna McLintock, MBChB, MD, MRCP, FRCPath, Christopher Poynton, DM, FRCP, FRCPath, Deepti Radia, MD
Journal: Blood
Blood (2011) 118 (21): 5145.
https://doi.org/10.1182/blood.V118.21.5145.5145
Published: 2011
Journal Articles

In essential thrombocythemia, multiple JAK2 -V617F clones are present in most mutant-positive patients: a new disease paradigm

Jonathan R. Lambert, Tamara Everington, David C. Linch, Rosemary E. Gale
Journal: Blood
Blood (2009) 114 (14): 3018–3023.
https://doi.org/10.1182/blood-2009-03-209916
Published: 2009
Includes: Supplemental data